Molecule Information

General Information of the Molecule (ID: Mol01873)

• Name: Fructose-bisphosphatase 1 (FBP1) ,Homo sapiens
• Synonyms: FBP1; FBP
• Molecule Type: Protein
• Gene Name: FBP1
• Gene ID: 2203
• Location: chr9:94,603,133-94,640,249[-]
• Sequence:
  MADQAPFDTDVNTLTRFVMEEGRKARGTGELTQLLNSLCTAVKAISSAVRKAGIAHLYGI
  AGSTNVTGDQVKKLDVLSNDLVMNMLKSSFATCVLVSEEDKHAIIVEPEKRGKYVVCFDP
  LDGSSNIDCLVSVGTIFGIYRKKSTDEPSEKDALQPGRNLVAAGYALYGSATMLVLAMDC
  GVNCFMLDPAIGEFILVDKDVKIKKKGKIYSLNEGYARDFDPAVTEYIQRKKFPPDNSAP
  YGARYVGSMVADVHRTLVYGGIFLYPANKKSPNGKLRLLYECNPMAYVMEKAGGMATTGK
  EAVLDVIPTDIHQRAPVILGSPDDVLEFLKVYEKHSAQ
• Function: Catalyzes the hydrolysis of fructose 1,6-bisphosphate to fructose 6-phosphate in the presence of divalent cations, acting as a rate-limiting enzyme in gluconeogenesis. Plays a role in regulating glucose sensing and insulin secretion of pancreatic beta-cells. Appears to modulate glycerol gluconeogenesis in liver. Important regulator of appetite and adiposity; increased expression of the protein in liver after nutrient excess increases circulating satiety hormones and reduces appetite-stimulating neuropeptides and thus seems to provide a feedback mechanism to limit weight gain.
• Uniprot ID: F16P1_HUMAN
• Ensembl ID: ENSG00000165140
• HGNC ID: HGNC:3606

Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens

Type(s) of Resistant Mechanism of This Molecule

  RTDM: Regulation by the Disease Microenvironment

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Doxorubicin

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Regulation by the Disease Microenvironment (RTDM)

Disease Class: B-cell non-Hodgkin lymphoma [1]

• Resistant Disease: B-cell non-Hodgkin lymphoma [ICD-11: 2A85.2]
• Resistant Drug: Doxorubicin
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: OCI-LY8 cells; Oral; Homo sapiens (Human); CVCL_8803
• In Vitro Model: Daudi cells; Peripheral blood; Homo sapiens (Human); CVCL_0008
• Experiment for Molecule Alteration: Immunoblot analysis
• Experiment for Drug Resistance: CCK-8 assay
• Mechanism Description: Cell adhesion mediated drug resistance (CAM DR) remains a major obstacle to the effectiveness of chemotherapeutic treatment of lymphoma. Far upstream element binding protein 1 (FBP1) is a multifunctional protein that is highly expressed in proliferating cells of several solid neoplasms. CAM-DR is considered a major mechanism by which tumor cells escape the cytotoxic effects of therapeutic agents.

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Regulation by the Disease Microenvironment (RTDM)

Disease Class: B-cell non-Hodgkin lymphoma [1]

• Sensitive Disease: B-cell non-Hodgkin lymphoma [ICD-11: 2A85.2]
• Sensitive Drug: Doxorubicin
• Molecule Alteration: Expression; Down-regulation
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: OCI-LY8 cells; Oral; Homo sapiens (Human); CVCL_8803
• In Vitro Model: Daudi cells; Peripheral blood; Homo sapiens (Human); CVCL_0008
• Experiment for Molecule Alteration: Immunoblot analysis
• Experiment for Drug Resistance: CCK-8 assay
• Mechanism Description: Cell adhesion mediated drug resistance (CAM DR) remains a major obstacle to the effectiveness of chemotherapeutic treatment of lymphoma. Far upstream element binding protein 1 (FBP1) is a multifunctional protein that is highly expressed in proliferating cells of several solid neoplasms. CAM-DR is considered a major mechanism by which tumor cells escape the cytotoxic effects of therapeutic agents.

References

• Ref 1: Expression of far upstream element binding protein 1 in B cell non Hodgkin lymphoma is correlated with tumor growth and cell adhesion mediated drug resistance .Mol Med Rep. 2016 Oct;14(4):3759-68. doi: 10.3892/mmr.2016.5718. Epub 2016 Sep 6. 10.3892/mmr.2016.5718